Pitavastatin

This classification denotes a hmg-coa reductase inhibitor with the molecular formula C25H24FNO4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier M5681Q5F9P, chemically known as 6-heptenoic acid, 7-(2-cyclopropyl-4-(4-fluorophenyl)-3-quinolinyl)-3,5-dihydroxy-, (s-(r*,s*-(e)))- but generally known as pitavastatin, which bears US NIH Compound Identifier 6366718. European Medicines Agency schedules Pitavastatin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB21363. The term PITAVASTATIN is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 15 No. 1, 2001, List 45). World Health Organization schedules pitavastatin in its Anatomical Therapeutic Chemical (ATC) Classification. Most nations schedule pitavastatin under HS 29334990 and SITC 51575. As of Q4 2014, PITAVASTATIN remains the US FDA Preferred Term for this commodity. Pitavastatin bears US NLM identifiers UMLS ID C1101838 and NCI Concept Code C87751. SMILES: Fc1ccc(c2c(c(nc3c2cccc3)C2CC2)/C=C/C(O)CC(O)CC(=O)O)cc1.